Maxim upgraded Cellectar Biosciences (CLRB) to Buy from Hold with a $10 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLRB:
- Cellectar Biosciences Charts Risky Path to Approvals
- Cellectar Biosciences price target lowered to $14 from $18 at Roth Capital
- Cellectar Biosciences reports FY25 EPS ($8.35) vs ($41.89) last year
- CLRB Upcoming Earnings Report: What to Expect?
- Five new option listings and fourteen option delistings on February 23rd